Alphinity Global Equity is an Managed Funds investment product that is benchmarked against Developed -World Index and sits inside the Foreign Equity - Large Fundamental Index. Think of a benchmark as a standard where investment performance can be measured. Typically, market indices like the ASX200 and market-segment stock indexes are used for this purpose. The Alphinity Global Equity has Assets Under Management of 79.11 M with a management fee of 1%, a performance fee of 0.41% and a buy/sell spread fee of 0.5%.
Continued resilience in US economic data and a notable drop in inflation have together raised hopes that the US Federal Reserve (Fed) is done hiking rates and that a ‘soft landing’ for the US economy is achievable. At the same time after over two years of steady deceleration, the latest US manufacturing Purchasing Managers Index (PMI) of 47.6 appears to be recovering from trough levels historically associated with cyclical recovery. These are all encouraging signs. Nevertheless, risks from the lagged, cumulative impact of Fed rate hikes remain and elsewhere data has been more mixed. China continues to struggle with a deepening property crisis and recent growth and inflation data in Europe has also been somewhat disappointing. So, while the growth outlook is certainly stronger than feared at the start of the year, visibility into 2024 remains low.
Corporate earnings reflect a similar picture. With fears of an imminent recession abating, negative revisions have slowed significantly and in fact inflected slightly positive recently. The second quarter season was better than expected, with beats, both by number and magnitude, higher than normal. Forward guidance remained mostly cautious, driving mixed price responses, however despite this, earnings expectations for both 2023 and 2024 have edged higher. For example, EPS revisions for ‘23/’24 earnings are +0.3%/+0.4% over the last three months, which is a notable improvement from the previous negative trend of -2% to -3% per quarter. At a sector level, dispersion is relatively wide and mixed from a cyclical perspective. Materials, Energy, Real Estate and Health Care all sharply negative, while Consumer Discretionary, IT Hardware & Semiconductors and Communication services have seen positive revisions.
So far this year, leadership has rotated back to growth stocks and away from defensives sectors such as Utilities, Real Estate and Consumer Staples. A notable feature has been extremely narrow leadership breadth, with the socalled ‘magnificent seven’ group of mega-cap growth stocks, which make up ~27% of the S&P 500 market capitalisation, having delivered ~72% of the YTD return through to end August (albeit an improvement from 112% at the end of May 2023). There has also been strength in some cyclical industry groups recently including Autos, Semiconductors, Retail and Capital Goods, which have responded positively to better-than-expected growth and rising bond yields. This is a complicated and challenging backdrop for financial markets, with clear and sustained earnings leadership remaining elusive.
Activity during the month was mostly stock specific. We initiated a new position in Novo Nordisk following positive trial results and higher conviction about the long-term potential for their obesity drugs to also address other comorbidities. We also added a position in Ferrari, a high-quality luxury automobile manufacturer with limited cyclicality. Fortinet and Keysight both reported broadly in-line results, however order/billings trends and guidance for both were unexpectedly weak. Earnings recovery is uncertain and consequently we exited both positions.
Overall, the portfolio remains well-positioned in strong growth stories, combined with some flagship defensives. We have recently added to our cyclical exposure where we have established stock-specific, fundamental earnings conviction; however, the portfolio overall remains relatively less invested in cyclical stocks. The investment team is again travelling widely overseas to meet companies across different sectors and geographies as the earnings cycle continues to evolve.
Product Snapshot
Performance Review
Product Overview
Peer Comparison
Product Details